Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veraxa Biotech Holding AGVRXA -0.66%6 Equity-to-Asset is 0.95 as of Dec. 2025, which is 157% above its 10-year median of 0.37. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Veraxa Biotech Holding AG ranks worse than 89.45% on this metric.
Veraxa Biotech Holding AG (NAS:VRXA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Veraxa Biotech Holding AG Equity-to-Asset Related Terms
Veraxa Biotech Holding AG Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG Equity-to-Asset Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
Equity-to-Asset
-0.07
0.95
0.95
Veraxa Biotech Holding AG Quarterly Data
Jun24
Dec24
Jun25
Dec25
Equity-to-Asset
-0.21
0.95
0.95
0.95
VRXA vs KRRO, CNXU, NKTX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's Equity-to-Asset falls into.
Veraxa Biotech Holding AG Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Veraxa Biotech Holding AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG (VRXA) has a Equity-to-Asset of 0.95 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Veraxa Biotech Holding AG and its competitors. This is 157% above median its historical median of 0.37. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #1263 out of 1412 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Veraxa Biotech Holding AG's Equity-to-Asset too high?
Veraxa Biotech Holding AG's current Equity-to-Asset of 0.95 is 157% above median its 10-year median of 0.37. The Biotechnology industry median Equity-to-Asset is 0.69. Veraxa Biotech Holding AG's value of 0.95 is 37.7% above this industry median. Based on the distribution chart, Veraxa Biotech Holding AG ranks #1263 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Equity-to-Asset compare to KRRO and CNXU?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #1263 out of 1412 companies for Equity-to-Asset. This places Veraxa Biotech Holding AG in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Veraxa Biotech Holding AG's value of 0.95 is 37.7% above this benchmark. While the company's 10-year median is 0.37 vs. the industry median of 0.69, Veraxa Biotech Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veraxa Biotech Holding AG's current Equity-to-Asset of 0.95 is 37.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Veraxa Biotech Holding AG and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veraxa Biotech Holding AG's current Equity-to-Asset is 0.95, which is 157% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Equity-to-Asset of 0.95. The current Equity-to-Asset is 0.95, which is 157% above median its 10-year median of 0.37 and 37.7% above the Biotechnology industry median of 0.69. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Equity-to-Asset is 0.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
